[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fP-0tqhVjaIt0NqZZeRLK5GPv2TY-bIhaVKJN0YhWh60":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Hellenic Cooperative Oncology Group",[4],53,false,3,0,21544,27,[13,16,19,21,23,26,28,31],{"name":14,"count":15},"Breast Cancer",9,{"name":17,"count":18},"Non Small Cell Lung Cancer",5,{"name":20,"count":8},"Metastatic Breast Cancer",{"name":22,"count":8},"Ovarian Cancer",{"name":24,"count":25},"Colorectal Cancer",2,{"name":27,"count":25},"Prostate Cancer",{"name":29,"count":30},"Melanoma",1,{"name":32,"count":30},"Malignant Glioma",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,81,117,151,177,204,222,249,273,300,318,336,359,387,413,431,457,486,514,532,550,568,591,617,642,668,696,724,752,778],{"intervention":43,"totalTrials":25,"cells":44},"Panitumumab",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":75,"PHASE4":77,"NA":79},{"trials":46,"activeCount":9},[],{"trials":48,"activeCount":9},[],{"trials":50,"activeCount":9},[51,63],{"nctId":52,"briefTitle":53,"status":54,"phases":55,"primaryCompletion":56,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":62},"NCT03311750","Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer","TERMINATED",[37],"2021-03-31","2021-05-20","2018-03-26",23,[61],"Advanced Colorectal Cancer",[43],{"nctId":64,"briefTitle":65,"status":66,"phases":67,"primaryCompletion":68,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":73},"NCT01215539","Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients","COMPLETED",[37],"2014-08","2014-12","2010-09",78,[24],[74],"panitumumab",{"trials":76,"activeCount":9},[],{"trials":78,"activeCount":9},[],{"trials":80,"activeCount":9},[],{"intervention":82,"totalTrials":25,"cells":83},"Cabazitaxel",{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":111,"PHASE4":113,"NA":115},{"trials":85,"activeCount":9},[],{"trials":87,"activeCount":9},[],{"trials":89,"activeCount":9},[90,100],{"nctId":91,"briefTitle":92,"status":66,"phases":93,"primaryCompletion":94,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":99},"NCT01693549","Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes",[37],"2017-07-10","2017-07-20","2012-09",84,[14],[82],{"nctId":101,"briefTitle":102,"status":66,"phases":103,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT02512458","Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer",[37],"2019-12","2019-12-27","2015-10-29",60,[109],"Bone Metastatic Prostate Cancer",[82],{"trials":112,"activeCount":9},[],{"trials":114,"activeCount":9},[],{"trials":116,"activeCount":9},[],{"intervention":118,"totalTrials":25,"cells":119},"Temsirolimus",{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":121,"activeCount":9},[],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[126,134],{"nctId":127,"briefTitle":128,"status":54,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":15,"conditions":132,"interventions":133},"NCT00926107","Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse",[37],"2011-10","2009-06",[22],[118],{"nctId":135,"briefTitle":136,"status":54,"phases":137,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT01264341","Efficacy and Safety of Bevacizumab\u002FTemsirolimus Combination to Treat Advanced Renal Cell Carcinoma",[37],"2015-07","2010-12",39,[142],"Kidney Cancer",[144,118],"Bevacizumab",{"trials":146,"activeCount":9},[],{"trials":148,"activeCount":9},[],{"trials":150,"activeCount":9},[],{"intervention":152,"totalTrials":30,"cells":153},"Ramucirumab",{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":155,"activeCount":9},[],{"trials":157,"activeCount":9},[],{"trials":159,"activeCount":9},[160],{"nctId":161,"briefTitle":162,"status":66,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT03745430","RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma",[36,37],"2022-06-17","2023-04-23","2019-01-29",54,[169],"Pancreatic Adenocarcinoma",[152],{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"intervention":178,"totalTrials":30,"cells":179},"Erlotinib, Docetaxel",{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":181,"activeCount":9},[],{"trials":183,"activeCount":9},[],{"trials":185,"activeCount":9},[186],{"nctId":187,"briefTitle":188,"status":54,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT00783471","Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)",[37],"2010-05","2010-06","2008-11",51,[195],"Advanced Non-Small Cell Lung Cancer",[178,197],"Docetaxel, Erlotinib",{"trials":199,"activeCount":9},[],{"trials":201,"activeCount":9},[],{"trials":203,"activeCount":9},[],{"intervention":197,"totalTrials":30,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":207,"activeCount":9},[],{"trials":209,"activeCount":9},[],{"trials":211,"activeCount":9},[212],{"nctId":187,"briefTitle":188,"status":54,"phases":213,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":214,"interventions":215},[37],[195],[178,197],{"trials":217,"activeCount":9},[],{"trials":219,"activeCount":9},[],{"trials":221,"activeCount":9},[],{"intervention":223,"totalTrials":30,"cells":224},"Cisplatin-5FU-Afatinib",{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":226,"activeCount":9},[],{"trials":228,"activeCount":9},[],{"trials":230,"activeCount":9},[231],{"nctId":232,"briefTitle":233,"status":66,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":242},"NCT01743365","Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer",[37],"2019-06-15","2019-07-29","2013-02-11",55,[240,241],"Gastric Cancer","Gastroesophageal Junction Cancer",[223],{"trials":244,"activeCount":9},[],{"trials":246,"activeCount":9},[],{"trials":248,"activeCount":9},[],{"intervention":250,"totalTrials":30,"cells":251},"ixabepilone",{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":253,"activeCount":9},[],{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[258],{"nctId":259,"briefTitle":260,"status":54,"phases":261,"primaryCompletion":262,"completion":263,"start":192,"enrollment":264,"conditions":265,"interventions":266},"NCT00790894","Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)",[37],"2011-04","2011-05",64,[20],[250,250],{"trials":268,"activeCount":9},[],{"trials":270,"activeCount":9},[],{"trials":272,"activeCount":9},[],{"intervention":274,"totalTrials":30,"cells":275},"Olaparib",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":277,"activeCount":9},[],{"trials":279,"activeCount":9},[],{"trials":281,"activeCount":9},[282],{"nctId":283,"briefTitle":284,"status":66,"phases":285,"primaryCompletion":104,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":291},"NCT02882308","Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.",[37],"2020-01-10","2016-10-20",41,[290],"Squamous Cell Carcinoma of the Head and Neck",[274,292,274,293],"Cisplatin","Durvalumab",{"trials":295,"activeCount":9},[],{"trials":297,"activeCount":9},[],{"trials":299,"activeCount":9},[],{"intervention":292,"totalTrials":30,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":303,"activeCount":9},[],{"trials":305,"activeCount":9},[],{"trials":307,"activeCount":9},[308],{"nctId":283,"briefTitle":284,"status":66,"phases":309,"primaryCompletion":104,"completion":286,"start":287,"enrollment":288,"conditions":310,"interventions":311},[37],[290],[274,292,274,293],{"trials":313,"activeCount":9},[],{"trials":315,"activeCount":9},[],{"trials":317,"activeCount":9},[],{"intervention":293,"totalTrials":30,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":321,"activeCount":9},[],{"trials":323,"activeCount":9},[],{"trials":325,"activeCount":9},[326],{"nctId":283,"briefTitle":284,"status":66,"phases":327,"primaryCompletion":104,"completion":286,"start":287,"enrollment":288,"conditions":328,"interventions":329},[37],[290],[274,292,274,293],{"trials":331,"activeCount":9},[],{"trials":333,"activeCount":9},[],{"trials":335,"activeCount":9},[],{"intervention":337,"totalTrials":30,"cells":338},"vinorelbine oral formulation",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":353,"PHASE4":355,"NA":357},{"trials":340,"activeCount":9},[],{"trials":342,"activeCount":9},[],{"trials":344,"activeCount":9},[345],{"nctId":346,"briefTitle":347,"status":66,"phases":348,"completion":349,"start":350,"conditions":351,"interventions":352},"NCT00278070","Metronomic Oral Vinorelbine in Patients With Metastatic Tumors",[37],"2008-02","2006-01",[14,17,27],[337],{"trials":354,"activeCount":9},[],{"trials":356,"activeCount":9},[],{"trials":358,"activeCount":9},[],{"intervention":360,"totalTrials":30,"cells":361},"Gemcitabine-Pazopanib",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":363,"activeCount":9},[],{"trials":365,"activeCount":9},[],{"trials":367,"activeCount":9},[368],{"nctId":369,"briefTitle":370,"status":54,"phases":371,"primaryCompletion":372,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":380},"NCT01855724","Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine\u002FPazopanib in Patients With Biliary Tree Cancer",[37],"2018-09-15","2018-09-28","2013-06-28",29,[377,378,379],"Cholangiocarcinoma","Gallbladder Carcinoma","Biliary Carcinoma",[360],{"trials":382,"activeCount":9},[],{"trials":384,"activeCount":9},[],{"trials":386,"activeCount":9},[],{"intervention":388,"totalTrials":30,"cells":389},"Lapatinib",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":391,"activeCount":9},[],{"trials":393,"activeCount":9},[],{"trials":395,"activeCount":9},[396],{"nctId":397,"briefTitle":398,"status":66,"phases":399,"primaryCompletion":68,"completion":69,"start":400,"enrollment":401,"conditions":402,"interventions":406},"NCT01218529","Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors",[37],"2010-10",82,[403,404,405],"Brain Metastases","Lung Tumors","Breast Tumors",[388],{"trials":408,"activeCount":9},[],{"trials":410,"activeCount":9},[],{"trials":412,"activeCount":9},[],{"intervention":144,"totalTrials":30,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":416,"activeCount":9},[],{"trials":418,"activeCount":9},[],{"trials":420,"activeCount":9},[421],{"nctId":135,"briefTitle":136,"status":54,"phases":422,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":423,"interventions":424},[37],[142],[144,118],{"trials":426,"activeCount":9},[],{"trials":428,"activeCount":9},[],{"trials":430,"activeCount":9},[],{"intervention":432,"totalTrials":30,"cells":433},"Avelumab",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":435,"activeCount":9},[],{"trials":437,"activeCount":9},[],{"trials":439,"activeCount":9},[440],{"nctId":441,"briefTitle":442,"status":443,"phases":444,"primaryCompletion":445,"completion":446,"start":447,"enrollment":238,"conditions":448,"interventions":450},"NCT03568097","Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer","UNKNOWN",[37],"2022-03-30","2024-04","2018-09-16",[449],"Small Cell Lung Carcinoma",[432],{"trials":452,"activeCount":9},[],{"trials":454,"activeCount":9},[],{"trials":456,"activeCount":9},[],{"intervention":458,"totalTrials":30,"cells":459},"Everolimus",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":461,"activeCount":9},[],{"trials":463,"activeCount":9},[],{"trials":465,"activeCount":9},[466],{"nctId":467,"briefTitle":468,"status":54,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":479},"NCT01648465","Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors",[37],"2017-01","2019-08-06","2012-08-06",25,[475,476,477,478],"Gastrointestinal Tumors","Pancreatic Tumors","Gastrointestinal Neuroendocrine Tumors","Pancreatic Neuroendocrine Tumors",[458],{"trials":481,"activeCount":9},[],{"trials":483,"activeCount":9},[],{"trials":485,"activeCount":9},[],{"intervention":487,"totalTrials":30,"cells":488},"AFLIBERCEPT",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":490,"activeCount":9},[],{"trials":492,"activeCount":9},[],{"trials":494,"activeCount":9},[495],{"nctId":496,"briefTitle":497,"status":66,"phases":498,"primaryCompletion":470,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":504},"NCT02129257","Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer",[37],"2017-09-25","2014-05-26",73,[503],"Metastatic Colorectal Cancer",[487,505,506,507],"Irinotecan","5-Fluorouracil","Folinic Acid",{"trials":509,"activeCount":9},[],{"trials":511,"activeCount":9},[],{"trials":513,"activeCount":9},[],{"intervention":505,"totalTrials":30,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":517,"activeCount":9},[],{"trials":519,"activeCount":9},[],{"trials":521,"activeCount":9},[522],{"nctId":496,"briefTitle":497,"status":66,"phases":523,"primaryCompletion":470,"completion":499,"start":500,"enrollment":501,"conditions":524,"interventions":525},[37],[503],[487,505,506,507],{"trials":527,"activeCount":9},[],{"trials":529,"activeCount":9},[],{"trials":531,"activeCount":9},[],{"intervention":506,"totalTrials":30,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":535,"activeCount":9},[],{"trials":537,"activeCount":9},[],{"trials":539,"activeCount":9},[540],{"nctId":496,"briefTitle":497,"status":66,"phases":541,"primaryCompletion":470,"completion":499,"start":500,"enrollment":501,"conditions":542,"interventions":543},[37],[503],[487,505,506,507],{"trials":545,"activeCount":9},[],{"trials":547,"activeCount":9},[],{"trials":549,"activeCount":9},[],{"intervention":507,"totalTrials":30,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":553,"activeCount":9},[],{"trials":555,"activeCount":9},[],{"trials":557,"activeCount":9},[558],{"nctId":496,"briefTitle":497,"status":66,"phases":559,"primaryCompletion":470,"completion":499,"start":500,"enrollment":501,"conditions":560,"interventions":561},[37],[503],[487,505,506,507],{"trials":563,"activeCount":9},[],{"trials":565,"activeCount":9},[],{"trials":567,"activeCount":9},[],{"intervention":569,"totalTrials":30,"cells":570},"Corellation of Mutations, TILs and Age in Breast Cancer",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":572,"activeCount":9},[],{"trials":574,"activeCount":9},[],{"trials":576,"activeCount":9},[],{"trials":578,"activeCount":9},[],{"trials":580,"activeCount":9},[],{"trials":582,"activeCount":9},[583],{"nctId":584,"briefTitle":569,"status":66,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":590},"NCT04033965",[],"2010-10-01","1997-09-03",345,[14],[569],{"intervention":592,"totalTrials":30,"cells":593},"Tumor molecular profiling",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":595,"activeCount":9},[],{"trials":597,"activeCount":9},[],{"trials":599,"activeCount":9},[],{"trials":601,"activeCount":9},[],{"trials":603,"activeCount":9},[],{"trials":605,"activeCount":9},[606],{"nctId":607,"briefTitle":608,"status":66,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":616},"NCT05573789","Tumor Molecular Profiling in Patients With Prostate Cancer",[],"2020-12-31","2022-09-01","2018-01-01",220,[27,615],"Metastatic Prostate Adenocarcinoma",[592],{"intervention":618,"totalTrials":30,"cells":619},"PARP inhibitor",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":621,"activeCount":9},[],{"trials":623,"activeCount":9},[],{"trials":625,"activeCount":9},[],{"trials":627,"activeCount":9},[],{"trials":629,"activeCount":9},[],{"trials":631,"activeCount":9},[632],{"nctId":633,"briefTitle":634,"status":443,"phases":635,"primaryCompletion":636,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT04724031","Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer",[],"2021-06-30","2023-09-30","2019-11-01",150,[22],[618],{"intervention":643,"totalTrials":30,"cells":644},"Combined DNA\u002FRNA sequencing on clinical FFPE material (technically challenging; innovative); immuno-genomics test.",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":646,"activeCount":9},[],{"trials":648,"activeCount":9},[],{"trials":650,"activeCount":9},[],{"trials":652,"activeCount":9},[],{"trials":654,"activeCount":9},[],{"trials":656,"activeCount":9},[657],{"nctId":658,"briefTitle":659,"status":66,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT06725342","HNSCC Immuno-genomics Project",[],"2019-07-01","2024-03-01","2014-12-19",401,[666],"Molecular Classification of HNSCC",[643],{"intervention":669,"totalTrials":30,"cells":670},"Checkpoint inhibitor",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":672,"activeCount":9},[],{"trials":674,"activeCount":9},[],{"trials":676,"activeCount":9},[],{"trials":678,"activeCount":9},[],{"trials":680,"activeCount":9},[],{"trials":682,"activeCount":9},[683],{"nctId":684,"briefTitle":685,"status":66,"phases":686,"primaryCompletion":687,"completion":688,"start":689,"enrollment":690,"conditions":691,"interventions":695},"NCT04805099","Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease",[],"2021-01-30","2021-02-28","2020-11-01",126,[692,693,694],"Autoimmune Diseases","Checkpoint Inhibitor","Immunotherapy",[669],{"intervention":697,"totalTrials":30,"cells":698},"Paclitaxel and ramucirumab",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":700,"activeCount":9},[],{"trials":702,"activeCount":9},[],{"trials":704,"activeCount":9},[],{"trials":706,"activeCount":9},[],{"trials":708,"activeCount":9},[],{"trials":710,"activeCount":9},[711],{"nctId":712,"briefTitle":713,"status":66,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":723},"NCT06666582","Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer",[],"2023-03-30","2024-01-15","2015-03-01",185,[720,721,722],"Gastric Cancer Stage IV","Second-line Treatment","Ramucirumab Paclitaxel",[697],{"intervention":725,"totalTrials":30,"cells":726},"Mutations",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":728,"activeCount":9},[],{"trials":730,"activeCount":9},[],{"trials":732,"activeCount":9},[],{"trials":734,"activeCount":9},[],{"trials":736,"activeCount":9},[],{"trials":738,"activeCount":9},[739],{"nctId":740,"briefTitle":741,"status":66,"phases":742,"primaryCompletion":638,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":751},"NCT03982446","Germline Mutations in Pancreatic Adenocarcinoma",[],"2020-01-03","2016-03-01",549,[747,748,749,750],"Germline Mutation Abnormality","Pancreatic Cancer","Predisposition, Genetic","Hereditary Cancer",[725],{"intervention":753,"totalTrials":30,"cells":754},"Antibody-Drug Conjugates",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":756,"activeCount":9},[],{"trials":758,"activeCount":9},[],{"trials":760,"activeCount":9},[],{"trials":762,"activeCount":9},[],{"trials":764,"activeCount":9},[],{"trials":766,"activeCount":9},[767],{"nctId":768,"briefTitle":769,"status":66,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":777},"NCT06504719","Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan",[],"2024-06-01","2024-09-01","2023-01-01",312,[14,776],"Metastatic Cancer",[753],{"intervention":779,"totalTrials":30,"cells":780},"Afatinib",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":782,"activeCount":9},[],{"trials":784,"activeCount":9},[],{"trials":786,"activeCount":9},[],{"trials":788,"activeCount":9},[],{"trials":790,"activeCount":9},[],{"trials":792,"activeCount":9},[793],{"nctId":794,"briefTitle":795,"status":66,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":804},"NCT04640870","The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib",[],"2020-03","2020-05","2015-03-15",59,[17,802,803],"EGF-R Positive Non-Small Cell Lung Cancer","EGFR Gene Mutation",[779]]